Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy

Journal of Cardiovascular Computed Tomography

Volumn 7, Issue 3, 2013, Pages 173-181

  Shiozaki, Afonso Akio ^a   Senra, Tiago ^a   Arteaga, Edmundo ^a   Martinelli Filho, Martino ^a   Pita, Cristiane Guedes ^a   Ávila, Luis Francisco R ^a   Parga Filho, José Rodrigues ^a   Mady, Charles ^a   Kalil Filho, Roberto ^a   Bluemke, David A ^b   Rochitte, Carlos Eduardo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Delayed enhancement cardiac computed tomography; Hypertrophic cardiomyopathy; Implantable cardiac defibrillator; Myocardial fibrosis; Ventricular arrhythmias

Indexed keywords

ADULT; ARTICLE; CARDIAC COMPUTER ASSISTED TOMOGRAPHY; CARDIOVASCULAR RISK; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HEART MUSCLE FIBROSIS; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MULTIDETECTOR COMPUTED TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

DELAYED ENHANCEMENT CARDIAC COMPUTED TOMOGRAPHY; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIAC DEFIBRILLATOR; MYOCARDIAL FIBROSIS; VENTRICULAR ARRHYTHMIAS;

ADOLESCENT; ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; DEFIBRILLATORS, IMPLANTABLE; ENDOMYOCARDIAL FIBROSIS; FEMALE; HUMANS; IOPAMIDOL; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RISK FACTORS; ROC CURVE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 84880148904     PISSN: 19345925     EISSN: 1876861X     Source Type: Journal    
DOI: 10.1016/j.jcct.2013.04.002     Document Type: Article

References (57)

1. Elliott P., McKenna W.J. Hypertrophic cardiomyopathy. Lancet 2004, 363:1881-1891.
2. Maron B.J. Sudden death in young athletes. NEngl J Med 2003, 349:1064-1075.
3. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. JAm Coll Cardiol 2003, 42:1687-1713.
4. Maron B.J., Shirani J., Poliac L.C., Mathenge R., Roberts W.C., Mueller F.O. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996, 276:199-204.
5. Cecchi F., Olivotto I., Montereggi A., Santoro G., Dolara A., Maron B.J. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. JAm Coll Cardiol 1995, 26:1529-1536.
6. Elliott P.M., Gimeno Blanes J.R., Mahon N.G., Poloniecki J.D., McKenna W.J. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001, 357:420-424.
7. Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. JAm Coll Cardiol 2000, 36:2212-2218.
8. Maron B.J., Savage D.D., Wolfson J.K., Epstein S.E. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981, 48:252-257.
9. McKenna W., Deanfield J., Faruqui A., England D., Oakley C., Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981, 47:532-538.
10. McKenna W.J., England D., Doi Y.L., Deanfield J.E., Oakley C., Goodwin J.F. Arrhythmia in hypertrophic cardiomyopathy, I: influence on prognosis. Br Heart J 1981, 46:168-172.
11. Sadoul N., Prasad K., Elliott P.M., Bannerjee S., Frenneaux M.P., McKenna W.J. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997, 96:2987-2991.
12. Spirito P., Bellone P., Harris K.M., Bernabo P., Bruzzi P., Maron B.J. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. NEngl J Med 2000, 342:1778-1785.
13. Anan R., Greve G., Thierfelder L., et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. JClin Invest 1994, 93:280-285.
14. Charron P., Dubourg O., Desnos M., et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998, 97:2230-2236.
15. Maron B.J., Niimura H., Casey S.A., Soper M.K., Wright G.B., Seidman J.G., et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein c gene mutations. JAm Coll Cardiol 2001, 38:315-321.
16. Niimura H., Bachinski L.L., Sangwatanaroj S., et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. NEngl J Med 1998, 338:1248-1257.
17. Thierfelder L., Watkins H., MacRae C., et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994, 77:701-712.
18. Watkins H., McKenna W.J., Thierfelder L., et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. NEngl J Med 1995, 332:1058-1064.
19. Rochitte C.E., Tassi E.M., Shiozaki A.A. The emerging role of MRI in the diagnosis and management of cardiomyopathies. Curr Cardiol Rep 2006, 8:44-52.
20. Vogel-Claussen J., Rochitte C.E., Wu K.C., Kamel I.R., Foo T.K., Lima J.A. Delayed enhancement MR imaging: utility in myocardial assessment. Radiographics 2006, 26:795-810.
21. Shiozaki A.A., Kim R.J., Parga J.R., Tassi E.M., Arteaga E., Rochitte C.E. Cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Arq Bras Cardiol 2007, 88:243-248.
22. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. JAm Coll Cardiol 2004, 43:2260-2264.
23. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. JAm Coll Cardiol 2002, 40:2156-2164.
24. Adabag A.S., Maron B.J., Appelbaum E., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. JAm Coll Cardiol 2008, 51:1369-1374.
25. Dimitrow P.P., Klimeczek P., Vliegenthart R., et al. Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia. Int J Cardiovasc Imaging 2008, 24:77-83. discussion 85-77.
26. Shirani J., Pick R., Roberts W.C., Maron B.J. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. JAm Coll Cardiol 2000, 35:36-44.
27. Teraoka K., Hirano M., Ookubo H., et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 2004, 22:155-161.
28. Bruder O., Wagner A., Jensen C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. JAm Coll Cardiol 2010, 56:875-887.
29. O'Hanlon R., Grasso A., Roughton M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. JAm Coll Cardiol 2010, 56:867-874.
30. Rubinshtein R., Glockner J.F., Ommen S.R., et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010, 3:51-58.
31. Alexandre J., Saloux E., Dugue A.E., et al. Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease. JCardiovasc Magn Reson 2013, 15:12.
32. Iles L., Pfluger H., Lefkovits L., et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. JAm Coll Cardiol 2011, 57:821-828.
33. Nazarian S., Hansford R., Roguin A., et al. Aprospective evaluation of a protocol for magnetic resonance imaging of patients with implanted cardiac devices. Ann Intern Med 2011, 155:415-424.
34. Kanal E., Borgstede J.P., Barkovich A.J., et al. American College of Radiology White Paper on MR Safety: 2004 update and revisions. AJR Am J Roentgenol 2004, 182:1111-1114.
35. Gerber B.L., Belge B., Legros G.J., et al. Characterization of acute and chronic myocardial infarcts by multidetector computed tomography: comparison with contrast-enhanced magnetic resonance. Circulation 2006, 113:823-833.
36. Lardo A.C., Cordeiro M.A., Silva C., et al. Contrast-enhanced multidetector computed tomography viability imaging after myocardial infarction: characterization of myocyte death, microvascular obstruction, and chronic scar. Circulation 2006, 113:394-404.
37. Shiozaki A.A., Santos T.S., Artega E., Rochitte C.E. Images in cardiovascular medicine. Myocardial delayed enhancement by computed tomography in hypertrophic cardiomyopathy. Circulation 2007, 115:e430-e431.
38. Berliner J.I., Kino A., Carr J.C., Bonow R.O., Choudhury L. Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 2013, 29:191-197.
39. Spirito P., Seidman C.E., McKenna W.J., Maron B.J. The management of hypertrophic cardiomyopathy. NEngl J Med 1997, 336:775-785.
40. Cecchi F., Maron B.J., Epstein S.E. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. JAm Coll Cardiol 1989, 13:1283-1288.
41. Maron B.J. Hypertrophic cardiomyopathy. Lancet 1997, 350:127-133.
42. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287:1308-1320.
43. Monserrat L., Elliott P.M., Gimeno J.R., Sharma S., Penas-Lado M., McKenna W.J. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. JAm Coll Cardiol 2003, 42:873-879.
44. Spirito P., Rapezzi C., Autore C., et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994, 90:2743-2747.
45. Spirito P., Maron B.J. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. JAm Coll Cardiol 1990, 15:1521-1526.
46. Ford W.R., Menon V., Bhambhani A., Liyanage R., Khan M.I., Jugdutt B.I. Changes in myocardial density during postinfarction healing: effect on estimation of invivo left ventricular mass by echocardiographic imaging. Can J Physiol Pharmacol 1997, 75:1075-1082.
47. Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. JAm Coll Cardiol 2003, 41:1561-1567.
48. Shiozaki A.A., Senra T., Arteaga E., et al. [Myocardial fibrosis in patients with hypertrophic cardiomyopathy and high risk for sudden death]. Arq Bras Cardiol 2010, 94:535-540. [in Portuguese].
49. Maron B.J., Roberts W.C., Epstein S.E. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982, 65:1388-1394.
50. Bello D., Fieno D.S., Kim R.J., et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. JAm Coll Cardiol 2005, 45:1104-1108.
51. Kwong R.Y., Chan A.K., Brown K.A., et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006, 113:2733-2743.
52. Wu K.C., Weiss R.G., Thiemann D.R., et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. JAm Coll Cardiol 2008, 51:2414-2421.
53. Yan A.T., Shayne A.J., Brown K.A., et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 2006, 114:32-39.
54. Maron B.J., Shen W.K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. NEngl J Med 2000, 342:365-373.
55. Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. JAm Coll Cardiol 2011, 58:e212-e260.
56. Tanaka M., Fujiwara H., Onodera T., Wu D.J., Hamashima Y., Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986, 55:575-581.
57. Noureldin R.A., Liu S., Nacif M.S., et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. JCardiovasc Magn Reson 2012, 14:17.